Brief: CytRx reports initial results of aldoxorubicin late-stage trial in soft tissue sarcoma patients

LadRx

11/07/2016 21:03

July 11 (Reuters) - Cytrx Announces Initial Results Of Phase 
3 Trial Of Aldoxorubicin In Patients With Second  
    * Line soft tissue sarcoma 
    * Study did not show significant difference between 
aldoxorubicin, investigator's choice therapy for pfs, with 
median of 4.17 months and 4.04 months 
    * Cytrx - study did not show significant difference between 
aldoxorubicin, investigator's choice therapy for primary end 
point 
    * Patients continue to be followed for overall survival , a 
secondary endpoint of trial 
 
Source text for Eikon:  ID:nPn2Wjnma  
Further company coverage:  CYTR.O  
 
 (Bengaluru Newsroom: +1-646-223-8780)